Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice
Authors:ID Omerzel, Maša (Author)
ID Jesenko, Tanja (Author)
ID Markelc, Boštjan (Author)
ID Janžič, Larisa (Author)
ID Čemažar, Maja (Author)
ID Serša, Gregor (Author)
Files:.pdf PDF - Presentation file, download (3,74 MB)
MD5: 1B2A7A6917FD419DB6A245FCA0640FF5
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Electrochemotherapy (ECT), a local therapy, has different effectiveness among tumor types. In breast can-cer, its effectiveness is low; therefore, combined therapies are needed. The aim of our study was to com-bine ECT with PARP inhibitor olaparib, which could inhibit the repair of bleomycin or cisplatin inducedDNA damage and potentiate the effectiveness of ECT. The effects of combined therapy were studied inBRCA1mutated (HCC1937) and non-mutated (HCC1143) triple negative breast cancer cell lines.Therapeutic effectiveness was studied in 2D and 3D cell cultures andin vivoon subcutaneousHCC1937 tumor model in mice. The underlying mechanism of combined therapy was determined withthe evaluation ofcH2AX foci. Combined therapy of ECT with bleomycin and olaparib potentiated theeffectiveness of ECT inBRCA1mutated HCC1937, but not in non-mutated HCC1143 cells. The combinedtherapy had a synergistic effect, which was due to the increased number of DNA double strand breaks.Addition of olaparib to ECT with bleomycinin vivoin HCC1937 tumor model had only minimal effect,indicating repetitive olaparib treatment would be needed. This study demonstrates that DNA repar inhibiting drugs, like olaparib, have the potential to increase the effectiveness of ECT with bleomycin.
Keywords:electrochemotherapy, breast cancer, olaparib, bleomycin
Publication status:Published
Publication version:Version of Record
Publication date:01.05.2021
Publisher:Elsevier
Year of publishing:2021
Number of pages:str. 107832-1-10783-12
Numbering:Vol. 140
PID:20.500.12556/DiRROS-15564 New window
UDC:602.6/.7
ISSN on article:1567-5394
DOI:10.1016/j.bioelechem.2021.107832 New window
COBISS.SI-ID:66822915 New window
Copyright:by Authors
Publication date in DiRROS:21.09.2022
Views:518
Downloads:185
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Bioelectrochemistry
Publisher:Elsevier
ISSN:1567-5394
COBISS.SI-ID:2502484 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1871-2019
Name:Kombinacija elektrokemoterapije in zaviralca poli (adenozin difosfat-riboza) polimeraze pri zdravljenju raka dojke

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003-2015
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:21.09.2022

Secondary language

Language:Slovenian
Keywords:elektrokemoterapija, rak dojke, olaparib, bleomycin


Back